Genmab A/S (GMAB.CO)
DKK 1486.5
(4.13%)
DKK 1486.5
(4.13%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 66.64 DKK | -20.08% |
| 2022 | 83.38 DKK | 81.26% |
| 2021 | 46.00 DKK | -36.99% |
| 2020 | 73.00 DKK | 112.21% |
| 2019 | 34.40 DKK | 43.15% |
| 2018 | 24.03 DKK | 32.47% |
| 2017 | 18.14 DKK | -8.52% |
| 2016 | 19.83 DKK | 51.95% |
| 2015 | 13.05 DKK | 143.93% |
| 2014 | 5.35 DKK | 287.68% |
| 2013 | 1.38 DKK | 157.02% |
| 2012 | -2.42 DKK | 49.58% |
| 2011 | -4.80 DKK | -50.47% |
| 2010 | -3.19 DKK | 58.84% |
| 2009 | -7.75 DKK | 64.15% |
| 2008 | -21.62 DKK | -116.85% |
| 2007 | -9.97 DKK | 18.01% |
| 2006 | -12.16 DKK | 11.43% |
| 2005 | -13.73 DKK | -197.51% |
| 2004 | 14.08 DKK | -1.74% |
| 2003 | 14.33 DKK | -33.13% |
| 2002 | 21.43 DKK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | 21.85 DKK | 7.69% |
| 2024 Q1 | 20.29 DKK | 107.04% |
| 2023 Q4 | 9.80 DKK | -69.94% |
| 2023 Q2 | 20.80 DKK | 501.16% |
| 2023 Q1 | 3.46 DKK | -61.25% |
| 2023 FY | - DKK | -20.08% |
| 2023 Q3 | 32.60 DKK | 56.73% |
| 2022 Q3 | 39.55 DKK | 36.99% |
| 2022 Q4 | 8.93 DKK | -77.42% |
| 2022 Q1 | 7.07 DKK | -35.43% |
| 2022 Q2 | 28.87 DKK | 308.35% |
| 2022 FY | - DKK | 81.26% |
| 2021 Q2 | 4.68 DKK | -72.08% |
| 2021 Q1 | 16.76 DKK | 88.1% |
| 2021 Q4 | 10.95 DKK | -19.54% |
| 2021 Q3 | 13.61 DKK | 190.81% |
| 2021 FY | - DKK | -36.99% |
| 2020 Q1 | 4.13 DKK | -82.02% |
| 2020 Q3 | 8.13 DKK | -84.33% |
| 2020 Q4 | 8.91 DKK | 9.59% |
| 2020 FY | - DKK | 112.21% |
| 2020 Q2 | 51.88 DKK | 1156.17% |
| 2019 FY | - DKK | 43.15% |
| 2019 Q4 | 22.97 DKK | 174.11% |
| 2019 Q3 | 8.38 DKK | 507.25% |
| 2019 Q2 | 1.38 DKK | 16.95% |
| 2019 Q1 | 1.18 DKK | -91.32% |
| 2018 Q2 | 4.26 DKK | 31.08% |
| 2018 FY | - DKK | 32.47% |
| 2018 Q4 | 13.59 DKK | 365.41% |
| 2018 Q3 | 2.92 DKK | -31.46% |
| 2018 Q1 | 3.25 DKK | -73.9% |
| 2017 FY | - DKK | -8.52% |
| 2017 Q2 | 5.05 DKK | 1770.37% |
| 2017 Q4 | 12.45 DKK | 13933.33% |
| 2017 Q3 | -0.09 DKK | -101.78% |
| 2017 Q1 | 0.27 DKK | -98.08% |
| 2016 Q2 | 2.82 DKK | 1584.21% |
| 2016 FY | - DKK | 51.95% |
| 2016 Q1 | -0.19 DKK | -102.87% |
| 2016 Q3 | 3.15 DKK | 11.7% |
| 2016 Q4 | 14.03 DKK | 345.4% |
| 2015 Q4 | 6.61 DKK | 177.73% |
| 2015 Q2 | 0.28 DKK | -92.63% |
| 2015 Q3 | 2.38 DKK | 750.0% |
| 2015 FY | - DKK | 143.93% |
| 2015 Q1 | 3.80 DKK | 211.48% |
| 2014 Q1 | 1.79 DKK | 59.82% |
| 2014 FY | - DKK | 287.68% |
| 2014 Q4 | 1.22 DKK | -56.74% |
| 2014 Q3 | 2.82 DKK | 713.04% |
| 2014 Q2 | -0.46 DKK | -125.7% |
| 2013 Q2 | -0.50 DKK | -183.33% |
| 2013 Q1 | 0.60 DKK | 281.82% |
| 2013 Q4 | 1.12 DKK | 1020.0% |
| 2013 FY | - DKK | 157.02% |
| 2013 Q3 | 0.10 DKK | 120.0% |
| 2012 Q1 | -1.38 DKK | -79.22% |
| 2012 Q2 | 0.19 DKK | 113.77% |
| 2012 Q3 | -0.96 DKK | -605.26% |
| 2012 Q4 | -0.33 DKK | 65.62% |
| 2012 FY | - DKK | 49.58% |
| 2011 Q1 | -2.25 DKK | -30.06% |
| 2011 Q2 | -1.59 DKK | 29.33% |
| 2011 Q4 | -0.77 DKK | -305.26% |
| 2011 FY | - DKK | -50.47% |
| 2011 Q3 | -0.19 DKK | 88.05% |
| 2010 Q1 | -2.57 DKK | 3.38% |
| 2010 FY | - DKK | 58.84% |
| 2010 Q3 | 2.78 DKK | 266.47% |
| 2010 Q4 | -1.73 DKK | -162.23% |
| 2010 Q2 | -1.67 DKK | 35.02% |
| 2009 Q2 | -1.12 DKK | 66.47% |
| 2009 FY | - DKK | 64.15% |
| 2009 Q1 | -3.34 DKK | 0.0% |
| 2009 Q4 | -2.66 DKK | -329.03% |
| 2009 Q3 | -0.62 DKK | 44.64% |
| 2008 FY | - DKK | -116.85% |
| 2007 FY | - DKK | 18.01% |
| 2006 FY | - DKK | 11.43% |
| 2005 FY | - DKK | -197.51% |
| 2004 FY | - DKK | -1.74% |
| 2003 FY | - DKK | -33.13% |
| 2002 FY | - DKK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| ALK-Abelló A/S | 2.20 DKK | -2929.091% |
| Bavarian Nordic A/S | 19.23 DKK | -246.542% |
| Gubra A/S | -2.93 DKK | 2374.403% |
| Novo Nordisk A/S | 18.67 DKK | -256.936% |
| Orphazyme A/S | -0.74 DKK | 9105.405% |
| Pharma Equity Group A/S | -0.02 DKK | 292380.702% |
| Zealand Pharma A/S | -12.44 DKK | 635.691% |